Advertisement
MCP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/mcp.R400006-MCP200 on February 5, 2004.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
R400006-MCP200v1
3/4/355    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Glossary
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobs, I. J.
Right arrow Articles by Menon, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobs, I. J.
Right arrow Articles by Menon, U.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular & Cellular Proteomics 3:355-366, 2004.
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc.

Review

Progress and Challenges in Screening for Early Detection of Ovarian Cancer*

Ian J. Jacobs{ddagger} and Usha Menon

From the Department of Gynaecological Oncology, Cancer Institute, Bart’s and The London, Queen Mary’s School of Medicine & Dentistry, London EC1M 6GR, United Kingdom

Ovarian cancer is characterize by few early symptoms, presentation at an advanced stage, and poor survival. As a result, it is the most frequent cause of death from gynecological cancer. During the last decade, a research effort has been directed toward improving outcomes for ovarian cancer by screening for preclinical, early stage disease using both imaging techniques and serum markers. Numerous biomarkers have shown potential in samples from clinically diagnosed ovarian cancer patients, but few have been thoroughly assessed in preclinical disease and screening. The most thoroughly investigated biomarker in ovarian cancer screening is CA125. Prospective studies have demonstrated that both CA125 and transvaginal ultrasound can detect a significant proportion of preclinical ovarian cancers, and refinements in interpretation of results have improved sensitivity and reduced the false-positive rate of screening. There is preliminary evidence that screening can improve survival, but the impact of screening on mortality from ovarian cancer is still unclear. Prospective studies of screening are in progress in both the general population and high-risk population, including the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), a randomized trial involving 200,000 postmenopausal women designed to document the impact of screening on mortality. Recent advances in technology for the study of the serum proteome offer exciting opportunities for the identification of novel biomarkers or patterns of markers that will have greater sensitivity and lead time for preclinical disease than CA125. Considerable interest and controversy has been generated by initial results utilizing surface-enhanced laser desorption/ionization (SELDI) in ovarian cancer. There are challenging issues related to the design of studies to evaluate SELDI and other proteomic technology, as well as the reproducibility, sensitivity, and specificity of this new technology. Large serum banks such as that assembled in UKCTOCS, which contain preclinical samples from patients who later developed ovarian cancer and other disorders, provide a unique resource for carefully designed studies of proteomic technology. There is a sound basis for optimism that further developments in serum proteomic analysis will provide powerful methods for screening in ovarian cancer and many other diseases.

{ddagger} To whom correspondence should be addressed: Department of Gynaecological Oncology, Cancer Institute, Bart’s and The London, Queen Mary’s School of Medicine & Dentistry, London EC1M 6GR, United Kingdom. Tel.: 20-7882-5959; Fax: 20-7882-5958; E-mail: i.j.jacobs{at}qmul.ac.uk


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. C. Lim, K.-C. Chun, S.-J. Shin, I. H. Lee, K. T. Lim, C. H. Cho, S.-Y. Park, and J.-H. Nam
Clinical Presentation of Endometrioid Epithelial Ovarian Cancer with Concurrent Endometriosis: A Multicenter Retrospective Study
Cancer Epidemiol. Biomarkers Prev., February 1, 2010; 19(2): 398 - 404.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. L. Anderson, M. McIntosh, L. Wu, M. Barnett, G. Goodman, J. D. Thorpe, L. Bergan, M. D. Thornquist, N. Scholler, N. Kim, et al.
Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study
J Natl Cancer Inst, January 6, 2010; 102(1): 26 - 38.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
H. Cho and J.-H. Kim
Lipocalin2 Expressions Correlate Significantly With Tumor Differentiation in Epithelial Ovarian Cancer
J. Histochem. Cytochem., May 1, 2009; 57(5): 513 - 521.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Coates, K. Kolor, S. L. Stewart, and L. C. Richardson
Diagnostic Markers for Ovarian Cancer Screening: Not Ready for Routine Clinical Use
Clin. Cancer Res., November 15, 2008; 14(22): 7575 - 7576.
[Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. M. Koomen, E. B. Haura, G. Bepler, R. Sutphen, E. R. Remily-Wood, K. Benson, M. Hussein, L. A. Hazlehurst, T. J. Yeatman, L. T. Hildreth, et al.
Proteomic Contributions to Personalized Cancer Care
Mol. Cell. Proteomics, October 1, 2008; 7(10): 1780 - 1794.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Drapkin, A. Clauss, and S. Skates
Urokinase-Type Plasminogen Activator Receptor: A Beacon of Malignancy?
Clin. Cancer Res., September 15, 2008; 14(18): 5643 - 5645.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Visintin, Z. Feng, G. Longton, D. C. Ward, A. B. Alvero, Y. Lai, J. Tenthorey, A. Leiser, R. Flores-Saaib, H. Yu, et al.
Diagnostic Markers for Early Detection of Ovarian Cancer
Clin. Cancer Res., February 15, 2008; 14(4): 1065 - 1072.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. G. Moore and R. C. Bast Jr
How Do You Distinguish a Malignant Pelvic Mass From a Benign Pelvic Mass? Imaging, Biomarkers, or None of the Above
J. Clin. Oncol., September 20, 2007; 25(27): 4159 - 4161.
[Full Text] [PDF]

Home page
 J Ultrasound MedHome page
A. Barua, J. S. Abramowicz, J. M. Bahr, P. Bitterman, A. Dirks, K. A. Holub, E. Sheiner, M. J. Bradaric, S. L. Edassery, and J. L. Luborsky
Detection of Ovarian Tumors in Chicken by Sonography: A Step Toward Early Diagnosis in Humans?
J. Ultrasound Med., July 1, 2007; 26(7): 909 - 919.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. B.J. Hermsen, S. von Mensdorff-Pouilly, J. Berkhof, P. J. van Diest, J. J.P. Gille, F. H. Menko, M. A. Blankenstein, P. Kenemans, and R. H.M. Verheijen
Serum CA-125 in Relation to Adnexal Dysplasia and Cancer in Women at Hereditary High Risk of Ovarian Cancer
J. Clin. Oncol., April 10, 2007; 25(11): 1383 - 1389.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Scholler, M. Crawford, A. Sato, C. W. Drescher, K. C. O'Briant, N. Kiviat, G. L. Anderson, and N. Urban
Bead-based ELISA for validation of ovarian cancer early detection markers.
Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2117 - 2124.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Moscova, D. J. Marsh, and R. C. Baxter
Protein Chip Discovery of Secreted Proteins Regulated by the Phosphatidylinositol 3-Kinase Pathway in Ovarian Cancer Cell Lines
Cancer Res., February 1, 2006; 66(3): 1376 - 1383.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. F. Chambers and B. C. Vanderhyden
Ovarian Cancer Biomarkers in Urine
Clin. Cancer Res., January 15, 2006; 12(2): 323 - 327.
[Full Text] [PDF]

Home page
 JCOHome page
I. Jacobs
Screening for Familial Ovarian Cancer: The Need for Well-Designed Prospective Studies
J. Clin. Oncol., August 20, 2005; 23(24): 5443 - 5445.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Mor, I. Visintin, Y. Lai, H. Zhao, P. Schwartz, T. Rutherford, L. Yue, P. Bray-Ward, and D. C. Ward
Serum protein markers for early detection of ovarian cancer
PNAS, May 24, 2005; 102(21): 7677 - 7682.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement